EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Patients' perspective, quality of life and treatment goals in Hailey–Hailey disease: Lessons learned from the German National Registry

D Rogner iD, L Heimerl, S Heyer, T Biedermann, E Sattler iD, A Zink iD

Journal of the European Academy of Dermatology and Venereology · 2024

DOI: 10.1111/jdv.19583 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2024. Verfasst von D Rogner und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergy, School of Medicine, Technical University of Munich, Munich, Germany. Hauptthemen laut MEDLINE: Pemphigus, Benign Familial, Darier Disease. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eva Luise und Horst Köhler Stiftung für seltene Erkrankungen, La Roche Posay Research Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hailey–Hailey disease (HHD) remains a difficult‐to‐treat dermatosis and little is known about the patient's perception of the disease activity, the treatment success and its impact on quality‐of‐life (QoL).

Objective

To obtain better understanding of HHD patients' needs regarding their medical condition, financial burden, QoL, subjective well‐being and treatment thereof as well as satisfaction to evaluate common treatments' ‘real‐life’ relevance.

Methods

With initiation of the national registry for Darier's disease (DD; Morbus Darier, MD) and Hailey–Hailey disease (HH) MDHHgermany, patients with HHD diagnosis were included starting June 2020. To assess subjective symptoms, patients filled out questionnaires such as the DLQI (dermatological life quality index), numeric rating scale (NRS) for itch, pain and burning sensation, as well as the SWLS (satisfaction with life scale) questionnaire to quantify overall satisfaction in life. Additionally, data on therapies were collected along with the patients’ satisfaction of those and their medical care. Furthermore, patients assessed financial aspects and work ability.

Results

One hundred and two patients were recruited from dermatology clinics, office‐based dermatologists and self‐help platforms across Germany between June 2020 and February 2023, 90 were eligible and analysed (mean: 49.91 years, 73.33% females, 26.67% males). 39.77% stated according to the DLQI their life is severely/very severely affected. Satisfaction with life was mediocre. Burning sensation was most pronounced among subjective symptoms (NRS 5.85 ± 2.80). Systemic treatments were rated as ineffective according to 56.92%, 25.56% had never received one. Most prescribed systemic treatments were corticosteroids (73.8%), followed by low‐dose naltrexone (LDN) (26.2%), retinoids (15.4%) and antibiotics (13.8%). Satisfaction with medical care was generally low.

Conclusion

Our ‘real‐life’ data state a major disease burden and impact on the QoL for affected individuals, as well as limited disease control due to inadequate therapies. MDHHgermany can provide insights into improvement of healthcare support with this debilitating disease and improve QoL. In the long term, it aims to provide basis for further clinical trials, epidemiological studies and immunological investigations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pemphigus, Benign FamilialDarier DiseaseMaleFemaleHumansQuality of LifeGoalsNaltrexone

Substanzen

Naltrexone

Autor:innen und Institutionen

  • Department of Dermatology and Allergy, School of Medicine, Technical University of Munich, Munich, Germany.
  • Department of Pharmacology and Toxicology, Rheinische Friedrich-Wilhelms-University Bonn, Bonn, Germany.
  • Department of Dermatology and Allergy, University Hospital, LMU Munich, Munich, Germany.
  • Division of Dermatology and Venereology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.

ORCID-Profile: D Rogner, E Sattler, A Zink

Förderung

  • Eva Luise und Horst Köhler Stiftung für seltene Erkrankungen
  • La Roche Posay Research Grant

Zitieren

APA

Rogner, D., Heimerl, L., Heyer, S., Biedermann, T., Sattler, E., & Zink, A. (2024). Patients' perspective, quality of life and treatment goals in Hailey–Hailey disease: Lessons learned from the German National Registry. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19583

Vancouver

Rogner D, Heimerl L, Heyer S, Biedermann T, Sattler E, Zink A. Patients' perspective, quality of life and treatment goals in Hailey–Hailey disease: Lessons learned from the German National Registry. Journal of the European Academy of Dermatology and Venereology. 2024. doi:10.1111/jdv.19583

BibTeX
@article{Rogner2024,
  author = {Rogner, D and Heimerl, L and Heyer, S and Biedermann, T and Sattler, E and Zink, A},
  title = {Patients' perspective, quality of life and treatment goals in Hailey–Hailey disease: Lessons learned from the German National Registry},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2024},
  doi = {10.1111/jdv.19583}
}
Kostenlos starten →